

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ENDYMED MEDICAL LTD., AND ENDYMED MEDICAL, INC.,¹
Petitioner,

v.

SERENDIA, LLC,
Patent Owner.

Case IPR2024-00386
Patent 9,480,836

**JOINT MOTION TO TERMINATE
INTER PARTES REVIEW**

¹ The Board, in IPR2024-00842, joined EndyMed Medical Ltd. and EndyMed Medical Inc. (“EndyMed”) as petitioners to this proceeding.

Patent Owner Serendia, LLC and Petitioners EndyMed Medical Ltd. and EndyMed Medical Inc. (collectively, “the Parties”) have reached a settlement. Pursuant to 35 U.S.C. § 317(a) and 37 C.F.R. §§ 42.72 and 42.74, the Parties jointly request termination of this *inter partes* review of U.S. Patent No. 9,480,836 (“Patent-in-Suit”). The Parties were authorized to file this Joint Motion by the Board via email on June 17, 2025.

As required under 35 U.S.C. § 317(b) and 37 C.F.R. §§ 42.74(b), a true copy of the confidential settlement agreement (Ex. 2161) that resolves the disputes in this *inter partes* review relating to the Patent-in-Suit is filed herewith as a confidential exhibit. There are no other collateral agreements, whether written or oral, between the Parties made in connection with, or in contemplation of, the termination sought. Exhibit 2161 forms the complete agreement resolving the disputes in the *inter partes* review between the Parties. The Parties have conferred on this matter, and the Parties are in agreement with this procedure.

Pursuant to 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c), the Parties are concurrently filing a Joint Request to Keep Separate, which asks the Board to treat the agreement as business confidential information, and to keep it separate from the files of this proceeding and the files of the Patent-in-Suit.

I. Statement Of Precise Relief Requested

The Parties jointly request that the Board terminate this *inter partes* review in its entirety.

II. Reasons Why Termination Is Appropriate

The Parties have reached an agreement resolving the underlying dispute in this *inter partes* review proceeding. Ex. 2161. Accordingly, termination of this *inter partes* review proceeding is appropriate because all disputes between the Parties regarding the Patent-in-Suit have been resolved. Motions to terminate based on a joint request are routinely granted in the pre-final written decision time frame before an oral hearing has been held.² An oral hearing has not been held, a final written decision has not issued, and termination is appropriate.

² See, e.g., *LG Electronics Inc. v. Pantech Wireless LLC*, IPR2023-01267, -01270, -01272 (P.T.A.B. Aug. 19, 2024) (Paper 34 at 2); *Meta Platforms, Inc. v. Thales Visionix, Inc.*, IPR2022-01298, -1301, -1302, -01303 (P.T.A.B. Feb. 22, 2024) (Paper 50 at 4); *Google LLC v. Jawbone Innovations, LLC*, IPR2022-00797 (P.T.A.B. Aug. 2, 2023) (Paper 25 at 3) (“Although the parties have completed briefing according to the Scheduling Order (Paper 13), the Board has not yet conducted an oral argument.”); *Nike, Inc. v. Point 3 Basketball, LLC*, IPR2016-00396 (P.T.A.B. Feb. 22, 2017) (Paper 20 at 3) (“Oral argument has not yet been

III. Conclusion

The Parties have settled all disputes relating to the Patent-in-Suit, and the Board has not issued a final written decision on the merits in this proceeding. Accordingly, the Parties respectfully request the Board to terminate this proceeding in its entirety.

Respectfully submitted,

Dated: June 18, 2025

By: / Charles H. Sanders /

Charles H. Sanders (Reg. No. 47,053)
charles.sanders@lw.com
Latham & Watkins LLP
200 Clarendon Street
Boston, MA 02116
Telephone: 617.948.6000
Fax: 617.948.6001
*Counsel for Patent Owner
Serendia, LLC*

Respectfully submitted,

Dated: June 18, 2025

By: / Guy Yonay /

Guy Yonay (Reg. No. 52,388)
gyonay@pearlcohen.com
Pearl Cohen Zedek Latzer Baratz LLP
7 Times Square Tower, 19th Fl.
New York, New York 10036
Telephone: 646-878-0808

held. Under these circumstances, we are persuaded that it is appropriate to terminate this proceeding with respect to both Petitioner and Patent Owner”).

Fax: 676-878-0801

Counsel for Petitioners

*EndyMed Medical Ltd. and EndyMed
Medical Inc.*

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. § 42.6(e), I certify that on this 18th day of June, 2025, a true and correct copy of the foregoing **Joint Motion to Terminate *Inter Partes* Review** was served by electronic mail on Petitioner's lead and backup counsel at the following email addresses:

Guy Yonay (Reg. No. 52,388)
Zeev Pearl (Reg. No. 60,234)
Kyle Auteri (Reg. No. 74,494)
Milo Eadan (Reg. No. 64,764)
Pearl Cohen Zedek Latzer Baratz LLP
7 Times Square Tower, 19th Fl.
New York, New York 10036
Tel: 646-878-0808
Facsimile: 676-878-0801
gyonay@pearlcohen.com
zpearl@pearlcohen.com
kauteri@pearlcohen.com
meadan@pearlcohen.com
endymed@pearlcohen.com

By: / Charles H. Sanders /

Charles H. Sanders (Reg. No. 47,053)
charles.sanders@lw.com
Latham & Watkins LLP
200 Clarendon Street
Boston, MA 02116
Telephone: 617.948.6000
Fax: 617.948.6001

*Counsel for Patent Owner
Serendia, LLC*